Skip to main content

Bain Capital Life Sciences Investors, LLC

13F filer · CIK 0001703031
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$1.68BU.S. long equity reported on 13F
Positions212 new · 1 closed
Net flow last quarter+$434MBuys minus sells
Top 10 positions weight87.9%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202621 positions
KLRAKailera Therapeutics, Inc.$498M29.58%17.42%NewQ2 2026
HTFLHeartflow, Inc.$248M14.74%9.74%-19.1%Q3 2025
NAMSNewAmsterdam Pharma Co N.V.$129M7.67%3.24%-47.9%Q4 2022
SVRASavara Inc$108M6.45%8.57%Not reportedQ4 2019
ALKSAlkermes plc.$102M6.04%1.16%+217.7%Q1 2026
SLDBSolid Biosciences Inc.$98M5.83%9.33%Not reportedQ1 2018
PHVSPharvaris N.V.$92.5M5.50%4.10%Not reportedQ1 2021
OLMAOlema Pharmaceuticals, Inc.$88.6M5.27%8.10%-5.2%Q4 2024
COAGHemab Therapeutics Holdings, Inc.$60.6M3.60%3.53%NewQ2 2026
CABACabaletta Bio, Inc.$53.6M3.19%10.57%+78.2%Q2 2023
XFORX4 Pharmaceuticals, Inc$37.2M2.21%8.29%Not reportedQ4 2019
DNTHDianthus Therapeutics, Inc.$35.3M2.10%0.66%Not reportedQ1 2024
CCCCC4 Therapeutics, Inc.$33.5M1.99%5.84%Not reportedQ4 2020
KYTXKyverna Therapeutics, Inc.$25.7M1.53%4.69%-7.2%Q1 2024
ANNXAnnexon, Inc.$25.3M1.51%2.97%-14.9%Q3 2020
RPIDRapid Micro Biosystems, Inc.$14.6M0.87%Not reportedNot reportedQ3 2021
IRONDisc Medicine, Inc.$10.3M0.61%0.37%Not reportedQ1 2023
AVIRAtea Pharmaceuticals, Inc.$9.65M0.57%2.59%-12.1%Q4 2020
XLOXilio Therapeutics, Inc.$6.36M0.38%10.09%Not reportedQ4 2021
UPBUpstream Bio, Inc.$4.16M0.25%1.10%-30.7%Q4 2024
NAMSWNewAmsterdam Pharma Co N.V.$2.14M0.13%Not reportedNot reportedQ4 2022
Q1 2026Reported May 15, 202620 positions
HTFLHeartflow, Inc.$254M22.93%12.13%-16.1%Q3 2025
NAMSNewAmsterdam Pharma Co N.V.$234M21.09%6.26%Not reportedQ4 2022
OLMAOlema Pharmaceuticals, Inc.$111M10.05%8.56%-12.2%Q4 2024
SVRASavara Inc$96.1M8.67%8.59%Not reportedQ4 2019
PHVSPharvaris N.V.$75.6M6.82%4.10%-4.5%Q1 2021
SLDBSolid Biosciences Inc.$70.6M6.37%9.97%+24.0%Q1 2018
XFORX4 Pharmaceuticals, Inc$32.9M2.97%8.45%Not reportedQ4 2019
DNTHDianthus Therapeutics, Inc.$30.4M2.74%0.66%-51.3%Q1 2024
ANNXAnnexon, Inc.$28.9M2.60%3.49%-0.7%Q3 2020
KYTXKyverna Therapeutics, Inc.$26.8M2.42%5.14%Not reportedQ1 2024
CABACabaletta Bio, Inc.$26M2.35%8.69%Not reportedQ2 2023
CNTACentessa Pharmaceuticals PLC$25.2M2.27%0.41%NewQ1 2026
ALKSAlkermes plc.$21.6M1.95%0.37%NewQ1 2026
RPIDRapid Micro Biosystems, Inc.$19.1M1.73%Not reportedNot reportedQ3 2021
CCCCC4 Therapeutics, Inc.$18.9M1.70%6.89%Not reportedQ4 2020
AVIRAtea Pharmaceuticals, Inc.$12.7M1.15%2.95%-5.0%Q4 2020
IRONDisc Medicine, Inc.$9.03M0.81%0.37%Not reportedQ1 2023
UPBUpstream Bio, Inc.$7.8M0.70%1.59%-34.8%Q4 2024
XLOXilio Therapeutics, Inc.$5.58M0.50%11.48%+26.1%Q4 2021
NAMSWNewAmsterdam Pharma Co N.V.$2M0.18%Not reportedNot reportedQ4 2022
Q4 2025Reported Feb 17, 202619 positions
HTFLHeartflow, Inc.$363M27.79%14.60%Not reportedQ3 2025
NAMSNewAmsterdam Pharma Co N.V.$256M19.63%6.39%-31.8%Q4 2022
OLMAOlema Pharmaceuticals, Inc.$213M16.29%10.46%+24.3%Q4 2024
SVRASavara Inc$106M8.13%8.60%Not reportedQ4 2019
PHVSPharvaris N.V.$77.8M5.96%4.30%-11.9%Q1 2021
SLDBSolid Biosciences Inc.$44.6M3.42%10.02%Not reportedQ1 2018
UPBUpstream Bio, Inc.$36.1M2.76%2.45%-45.5%Q4 2024
XFORX4 Pharmaceuticals, Inc$31.9M2.44%8.76%+227.0%Q4 2019
DNTHDianthus Therapeutics, Inc.$30.6M2.35%1.72%-43.5%Q1 2024
KYTXKyverna Therapeutics, Inc.$29.2M2.24%5.15%-7.7%Q1 2024
ANNXAnnexon, Inc.$26.4M2.02%3.51%Not reportedQ3 2020
RPIDRapid Micro Biosystems, Inc.$24.5M1.87%Not reportedNot reportedQ3 2021
CABACabaletta Bio, Inc.$21.2M1.62%9.63%Not reportedQ2 2023
CCCCC4 Therapeutics, Inc.$13.7M1.05%7.40%+545.0%Q4 2020
MRSNMersana Therapeutics, Inc.$10M0.77%6.93%Not reportedQ2 2020
AVIRAtea Pharmaceuticals, Inc.$8.87M0.68%3.18%Not reportedQ4 2020
TNGXTango Therapeutics, Inc.$5.79M0.44%0.48%-75.9%Q3 2021
XLOXilio Therapeutics, Inc.$4.72M0.36%162.73%+61.4%Q4 2021
NAMSWNewAmsterdam Pharma Co N.V.$2.3M0.18%Not reported0.0%Q4 2022
Q3 2025Reported Nov 14, 202521 positions
HTFLHeartflow, Inc.$419M27.81%14.91%NewQ3 2025
NAMSNewAmsterdam Pharma Co N.V.$305M20.23%9.47%Not reportedQ4 2022
CDTXCidara Therapeutics, Inc.$289M19.20%10.30%+20.8%Q3 2024
PHVSPharvaris N.V.$79.4M5.27%5.85%-3.7%Q1 2021
OLMAOlema Pharmaceuticals, Inc.$67M4.45%9.97%Not reportedQ4 2024
SVRASavara Inc$62.8M4.17%10.18%Not reportedQ4 2019
DNTHDianthus Therapeutics, Inc.$51.8M3.44%3.07%-47.0%Q1 2024
SLDBSolid Biosciences Inc.$48.8M3.24%10.16%Not reportedQ1 2018
UPBUpstream Bio, Inc.$45.9M3.05%4.52%Not reportedQ4 2024
RPIDRapid Micro Biosystems, Inc.$28.2M1.87%Not reportedNot reportedQ3 2021
TNGXTango Therapeutics, Inc.$22.8M1.51%2.43%Not reportedQ3 2021
CABACabaletta Bio, Inc.$22.6M1.50%10.05%Not reportedQ2 2023
KYTXKyverna Therapeutics, Inc.$20.2M1.34%7.69%Not reportedQ1 2024
ANNXAnnexon, Inc.$16M1.06%4.80%Not reportedQ3 2020
XFORX4 Pharmaceuticals, Inc$8.33M0.55%9.69%+332.1%Q4 2019
AVIRAtea Pharmaceuticals, Inc.$7.21M0.48%3.18%Not reportedQ4 2020
XLOXilio Therapeutics, Inc.$3.85M0.26%8.81%Not reportedQ4 2021
MRSNMersana Therapeutics, Inc.$2.69M0.18%6.93%-96.0%Q2 2020
CCCCC4 Therapeutics, Inc.$2.47M0.16%1.50%Not reportedQ4 2020
IPSCCentury Therapeutics, Inc.$1.76M0.12%4.09%-34.6%Q2 2024
NAMSWNewAmsterdam Pharma Co N.V.$1.71M0.11%Not reportedNot reportedQ4 2022
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.